Table 4.
Demographics and Effect of CFTR modulators on alpha diversity.
| CFTR no (n = 12 study participants) | CFTR yes (n = 5 study participants) | HC (n = 35 study participants) | P value | |
|---|---|---|---|---|
| Inhaled antibiotics (n, % yes) | 2 (17) | 1 (20) | NA | >0.999 |
| Antibiotics Courses in the 12 months Preceding Sample Collection (n, %)† | <0.001 (all) >0.999 (CFTR no vs yes) |
|||
| None | 0 (0) | 0 (0) | 27 (77) | |
| 1–2 courses | 5 (42) | 2 (40) | 8 (23) | |
| 3–4 courses | 4 (33) | 2 (40) | 0 (0) | |
| 5 or more courses | 3 (25) | 1 (20) | 0 (0) | |
| Total Visits during the Study Period (mean, SD)‡ | 4.3 (0.45) | 5 (0.71) | NA | 0.029 |
| Sick Visits during the Study Period (mean, SD)‡ | 1.1 (1.24) | 0.8 (0.84) | NA | 0.781 |
| Antibiotic Courses in the Study Period (mean, SD)‡ | 1.1 (1.24) | 0.8 (0.84) | NA | 0.781 |
| CFTR no (n = 51 study samples) | CFTR yes (n = 25 study samples) | HC (n = 35 study samples) | P value | |
| Number of OTUs∗ (mean, standard error) | 63.7 (4.9) | 74.7 (7.4) | 97.6 (4.4) | <0.001 |
| Shannon Diversity Index∗ (mean, standard error) | 2.11 (0.07) | 2.34 (0.10) | 2.56 (0.07) | <0.001 |
| Inverse Simpson Index∗ (mean, standard error) | 5.78 (0.41) | 7.23 (0.59) | 7.96 (0.43) | <0.001 |
CFTR, cystic fibrosis transmembrane conductance regulator; HC, healthy control.
†
Fisher's exact test.
‡
Wilcoxon rank-sum test.
∗
Mixed effects generalized linear model, adjusting for repeated patient visits.